Explore the Agenda

8:45 am Registration & Coffee

9:20 am Chair’s Opening Remarks

Developing Regulatory Confidence Through Stronger Quality Standards & Material Risk Assessment

9:30 am Creating Confidence Through Raw Materials Quality Standards for Cell & Gene Therapies

Senior Scientist, Global Biologics, U.S. Pharmacopeia
  • Discussing USP Chapter <1043> on ancillary material quality, risk assessment and material qualification
  • Noting recent developments in compendial methods for raw materials

10:00 am Interactive Discussion: Ask the USP

Senior Scientist, Global Biologics, U.S. Pharmacopeia
  • Opening up discussion on proposed revisions to USP Chapter 1043, with a focus on the 4-tier risk assessment system
  • Bringing together differing views on the tiered approach, encouraging participants to share perspectives and challenge assumptions
  • Exploring what these potential changes mean in practice for raw material risk assessment and decision-making

10:45 am Morning Break & Networking

Ensuring Manufacturing Consistency & Supply Continuity to Improve Safety & Reduce Disruption

11:45 am Reducing Safety Risk & Improving Consistency in Next Generation Allogeneic Treg Manufacturing

Chief Technical Officer, Tr1x therapeutics
  • Enabling mid process purification to achieve best-in-class drug product purity
  • Reducing graft versus host disease risk through tighter process control
  • Designing raw material and supply strategies with late-stage trials and commercial scale in mind

12:15 pm Panel Session: Navigating Supplier Diversification to Reduce Risk & Maintain Product Continuity

Associate Director, Raw Materials, Drug Product Process Development, Bristol Myers Squibb
Director, Head of Material Development, Kite Pharma Inc
  • Addressing challenges in qualifying secondary suppliers for critical materials
  • Understanding comparability and change control requirements when switching vendors
  • Balancing supply chain flexibility with IP constraints

1:15 pm Lunch Break & Networking

Building Stronger Buyer–Supplier Alignment to Enable Reliable, Scalable Raw Material Strategies

2:15 pm Roundtable Discussion: Defining What Biopharma Needs from Raw Material Suppliers to Enable Scalable, Reliable CGT Manufacturing

na, Independent Expert
  • Aligning expectations on material quality, data transparency, and change control to reduce downstream risk
  • Understanding where current supplier offerings fall short across development through commercial scale
  • Defining what strong partnerships look like in practice, from early engagement to long-term collaboration

2:45 pm Strengthening Shelf-Life Strategies for Raw Materials

Principal Scientist II, Johnson & Johnson Innovative Medicine.
  • Aligning shelf-life approaches across sites and CDMOs while leveraging supplier data and scientific justifications
  • Assessing chemical sensitivities and microbial risk in order to support the shelf-life decisions
  • Developing strategies to mitigate gaps in supplier stability data

3:15 pm End of the 3rd Raw Materials for Cell & Gene Therapy Summit